U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890636) titled 'Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC' on Oct. 16.
Brief Summary: Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has become an important treatment strategy for resectable non-small cell lung cancer (NSCLC). However, patients who do not achieve a pathological complete response (non-pCR) after neoadjuvant treatment remain at a high risk of disease recurrence, and optimal postoperative adjuvant treatment for these patients remains unclear. Adebrelimab, an immune checkpoint inhibitor targeting PD-L1, and famitinib, a multitarget tyrosine kinase inhibitor with antiangiogenic activity, m...